T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to the induction of a powerful immune response. The ...
The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the ...
For many doctors and researchers, immunotherapy that uses someone’s own immune system to target and attack cancer cells is the next and best frontier of cancer treatment.
Moffitt Cancer Center announces today a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell (CAR T) and T ...